Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer immunotherapy
21
×
biotech
life sciences
national blog main
national
national top stories
san francisco blog main
boston blog main
new york blog main
san francisco top stories
boston top stories
new york top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
fda
deals
startups
clinical trials
investing
novartis
pfizer
nonalcoholic steatohepatitis
alzheimer's disease
bristol-myers squibb
eli lilly
What
roundup
bio
cancer
companies
drug
biotech
days
ipo
life
new
science
week
bristol
clinical
develop
momentum
myers’s
nash
news
patients
pfizer’s
treatment
year
according
acquisition
acquisitions
ahead
alzheimer’s
amid
anniversary
annual
approaches
attention
bn
bombast
caught
celgene
ceo
chief
company’s
Language
unset
unknown
Current search:
" cancer immunotherapy "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@techcrunch.com
7 years ago
Sean Parker’s cancer institute may have found a blood test to find out if patients will respond to treatment